THE ROLE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND GLIFLOZINS IN THE TREATMENT OF CHRONIC HEART FAILURE WITH ANEMIA
Abstract
The article compares the effect of standard treatments containing gliflozins, i.e. glucose sodium cotransporter type 2 inhibitor dapagliflozin (forsiga) on hematological changes, intracardiac hemodynamics, kidney function, in particular glomerular filtration rate and collagen Ⅳ indicators in urine in patients with chronic heart failure anemia studied. The increase in erythropoietin levels in the group of patients who received dapagliflozin after treatment is related to the effect of the drug on stimulating the production of erythropoietin in the kidney. It is also confirmed that the effective reduction of the amount of collagen Ⅳ in the urine after the treatment has an effective effect of the drug on the fibrosis processes in the kidney.
Keywords
chronic heart failure, dapagliflozin, glomerular filtration rate, collagen IVHow to Cite
References
Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med.2009;361(25):2436-48. doi: 10.1056/NEJMoa0908355.
Caughey M.C., Avery C.L., Ni H., Solomon S.D., Matsushita K., Wruck L.M. et al. Outcomes of patients with anemia and acute decompensated heart failure with preserved versus reduced ejection fraction (from the ARIC study community surveillance). Am. J. Cardiol. 2014; 114(12): 1850–4. DOI: 10.1016/j. amjcard.2014.09.024.
De Silva R., Rigby A. S., Witte K. K., Nikitin N. P., Tin L., Goode K., Bhandari S., Clark A. L., Cleland J. G. Anemia, renal dysfunction, and their interaction in patients with chronic heartfailure // Am J Cardiol. – 2006. – Vol. 98. – P. 391-398.
Docherty KF, Curtain JP, Anand IS, Bengtsson O, Inzucchi SE, Køber L, et al. Effect of dapagliflozin on anaemia in DAPA-HF. Eur J Heart Fail. 2021;23(4):617-628. doi: 10.1002/ejhf.2132.
Docherty KF, Petrie MC. Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure. Heart. 2022;108(4):312-320. doi: 10.1136/heartjnl-2020-318658.
Ferreira JP, Anker SD, Butler J, Filippatos G, Iwata T, Salsali A, et al. Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced. Eur J Heart Fail. 2022;24(4):708-715. doi: 10.1002/ejhf.2409.
Filippatos G, Farmakis D, Colet JC, Dickstein K, Lüscher TF, Willenheimer R, et al. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. Eur J Heart Fail.2013;15(11):1267-76. doi: 10.1093/eurjhf/hft099]
Gadayev A.G., Turaqulov R.I., Kurbanov A.K., Rahimova M.E. Role of Hepcidin and Pro-Inflammatory Cytocines in Chonic Heart Failure in Combination with Anemia // Central Asian Journal of medicine.-2019., Vol.2019: Iss 3, Article 11., P. 81-92.
Krzysztofik JM, Sokolski M, Kosowski M, et al. Acute heart failure in patients admitted to the emergency department with acute myocardial infarction. Kardiol Pol. 2017; 75: 306-315.
Martens P, Nijst P, Verbrugge FH, et al. Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction. Acta Cardiol. 2018; 73: 115-123.
Mazer CD, Hare GMT, Connelly PW, Gilbert RE, Shehata N, Quan A, et al. Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation. 2020;141(8):704-707. doi: 10.1161/CIRCULATIONAHA.119.044235].
Nemeth E., Rivera S., Gabayan V. IL 6 mediates hypoferremiain in-flammation by inducing the synthesis of the iron regulatoryhormone hepcidin // J Clin Invest. – 2004. – Vol. 113, №9. – P. 1271–1276.
Oudejans I., Mosterd A., Bloemen J.A. et al. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests // European journal of heart failure. - 2011. - T. 13. -№. 5. - C. 518- 527.
Ponikowski P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart fai lure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail.2016; 18(8): 891-975.
Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J. S. et al. Рекомендации ESK по диагностике и лечению острой и хронической сердечной недостаточности 2016. Рос. кардиол. журн. 2017; 1(141).
Rizzo C, Carbonara R, Ruggieri R, et al. Iron deficiency: a new target for patients with heart failure. Front Cardiovasc Med. 2021;908. doi:10.3389/fcvm.2021.709872.
Swedberg K., Young J.B., Anand I.S., et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N. Engl. J. Med. 2013; 368(13): 1210– 1219.
van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Böhm M, Doletsky A, et al. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. Circulation. 2017; 136(15):1374-1383. doi: 10.1161/CIRCULATIONAHA.117.027497.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117-28. doi:10.1056/NEJMoa1504720.
Захидова К. Х. Выбор оптимальной терапии при коррекции анемического синдрома у больных с хронической сердечной недостаточностью. Кардиология. 2018;1:25-31. doi:10.18087/cardio.2018.1.10076.
Кобалава Ж.Д., Медовщиков В.В., Ешниязов Н.Б. На пути к квадротерапии сердечной недостаточности с низкой фракцией выброса: данные вторичных анализов DAPA-HF. // Российский кардиологический журнал. 2020; 25(5): 3870. с. 71-80.
Корбут А.И., Климонтов В.В. Эмпаглифлозин: новая стратегия нефропротекции при сахарном диабете. // Сахарный диабет. 2017; 20 (1): с. 75-84.
Мареев В.Ю. et al. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). Общество специалистов по сердечной недостаточности: Москва. 2016; 92.
Соломахина Н.И., Находнова Е.С., Ершов В.И. Анемия при хронической сердечной недостаточности: роль гепсидина как универсального регулятора метаболизма железа. Журн. Сердеч. Недостаточность. 2014; 85(4): 254–60.
Ткаченко E. И., Боровкова Н.Ю., Буянова М.В. Анемия при хронической сердечной недостаточности: взгляд на патогенез и пути коррекции. Доктор.Ру. 2019;2(157):31-6. doi:10.31550/1727-2378-2019-157-2-31-36.
License
Copyright (c) 2023 A. G. Gadaev, F. I. Khujakulova
This work is licensed under a Creative Commons Attribution 4.0 International License.
